Urolume stents in the management of benign UUrorluolmuem set esntetns tisn i nth teh me amnaangaegmeemnetn otf o bfe bneingnign Urolume stents in the management of benign prostatic hyperplasia prporsotastiact ihc yhpyepreprlapslaiasia prostatic hyperplasia Introduction IntIrnotdruodctuicotnion Introduction : J. C. D. Png and C. R. Chapple J. CJ..  CD..  DPn. Pg nagn da nCd.  CR. RC.h Caphpalpeple J. C. D. Png and C. R. Chapple

doi:10.3109/9780203427910-101

Chapter

Urolume stents in the management of benign UUrorluolmuem set esntetns tisn i nth teh me amnaangaegmeemnetn otf o bfe bneingnign Urolume stents in the management of benign prostatic hyperplasia prporsotastiact ihc yhpyepreprlapslaiasia prostatic hyperplasia Introduction IntIrnotdruodctuicotnion Introduction

Chapter

ABSTRACT

Introduction Benign prostatic hyperplasia (BPH) occurs histologically in approximately 50% of men at the age of 60 and in nearly 100% of men by 80 years.1 It has been estimated that the prevalence of ‘clinical’ BPH, defined as an enlargement of the prostate gland to a weight of more than 20 g in the presence of symptoms and/or a urinary flow rate of less than 15 ml/s and without evidence of malignancy was 253/1000 in a sample of 705 men aged 40-79 registered with a group general practice in Scotland.2 In the USA, Glynn et al.3 calculated the chance of a 40-year-old-man subsequently requiring a prostatectomy as 29%.